These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15391091)

  • 1. Experimental cardiac hypertrophy, rate of development and effect of adrenalectomy.
    RATHER LJ
    Am J Physiol; 1949 Oct; 159(1):153-9. PubMed ID: 15391091
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of adrenals on development of pressure-induced myocardial hypertrophy.
    Nichols JR; Clancy RL; Gonzalez NC
    Am J Physiol; 1983 Feb; 244(2):H234-8. PubMed ID: 6218759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INFLUENCE OF ADRENAL HORMONES ON THE ULTRASTRUCTURE OF THE HEART MUSCLE UNDER NORMAL WORKING CONDITIONS AND DURING ELEVATED PRESSURE WORK.
    BOEZNER A; BARTA E; PAVLOVICOVA H; MRENA E
    Cor Vasa; 1965; 7():227-31. PubMed ID: 14333178
    [No Abstract]   [Full Text] [Related]  

  • 4. [EFFECT OF A FACTOR DAMAGING CHROMOSOMAL DNA ON THE DEVELOPMENT OF COMPENSATORY CARDIAC HYPERTROPHY].
    BAZARDZHIAN AG; LEIKINA EM; ANTIPOVA KK
    Dokl Akad Nauk SSSR; 1964 Mar; 155():685-7. PubMed ID: 14236080
    [No Abstract]   [Full Text] [Related]  

  • 5. The antihypertensive agent cicletanine reverses vascular hyperreactivity to noradrenaline and cardiac hypertrophy in DOCA-salt rats.
    Castro A; Parra L; Alsasua A; Fuentes JA
    Arch Int Pharmacodyn Ther; 1990; 307():109-18. PubMed ID: 2151359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental and Human Evidence for Lipocalin-2 (Neutrophil Gelatinase-Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and heart failure.
    Marques FZ; Prestes PR; Byars SG; Ritchie SC; Würtz P; Patel SK; Booth SA; Rana I; Minoda Y; Berzins SP; Curl CL; Bell JR; Wai B; Srivastava PM; Kangas AJ; Soininen P; Ruohonen S; Kähönen M; Lehtimäki T; Raitoharju E; Havulinna A; Perola M; Raitakari O; Salomaa V; Ala-Korpela M; Kettunen J; McGlynn M; Kelly J; Wlodek ME; Lewandowski PA; Delbridge LM; Burrell LM; Inouye M; Harrap SB; Charchar FJ
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28615213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn.
    Pozzan GB; Armanini D; Cecchetto G; Opocher G; Rigon F; Fassina A; Zacchello F
    J Endocrinol Invest; 1997 Feb; 20(2):86-9. PubMed ID: 9125489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Nigella sativa- and exercise-induced models of cardiac hypertrophy: structural and electrophysiological features.
    Al-Asoom LI; Al-Shaikh BA; Bamosa AO; El-Bahai MN
    Cardiovasc Toxicol; 2014 Sep; 14(3):208-13. PubMed ID: 24448711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
    Hanada K; Asari K; Saito M; Kawana J; Mita M; Ogata H
    Eur J Pharmacol; 2008 Jul; 589(1-3):194-200. PubMed ID: 18534575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of zhimu and huangqi on cardiac hypertrophy and response to stimulation in mice].
    Hu YC; Hou JY
    Zhongguo Zhong Yao Za Zhi; 2003 Apr; 28(4):369-74. PubMed ID: 15139154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental cardiac hypertrophy induced by isoproterenol in the rat.
    Szabó J; Csáky L; Szegi J
    Acta Physiol Acad Sci Hung; 1975; 46(3):281-5. PubMed ID: 143367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart rate variability in two models of cardiac hypertrophy in rats in relation to the new molecular phenotype.
    Carré F; Maison-Blanche P; Ollivier L; Mansier P; Chevalier B; Vicuna R; Lessard Y; Coumel P; Swynghedauw B
    Am J Physiol; 1994 May; 266(5 Pt 2):H1872-8. PubMed ID: 8203586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of guanylic nucleotides on the work capacity as well as on cardiac and adrenal hypertrophy in rats].
    KOKAS E; MICZBAN I
    Int Z Vitaminforsch Beih; 1961 Feb; 11():310-9. PubMed ID: 13757661
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiac hypertrophy in experimental hypertension and its regression following reestablishment of normal blood pressure.
    HALL O; HALL CE; OGDEN E
    Am J Physiol; 1953 Jul; 174(1):175-8. PubMed ID: 13065516
    [No Abstract]   [Full Text] [Related]  

  • 15. State-of-the-Art Prevention of Heart Failure: Maladaptive versus Adaptive Hypertrophy.
    Condorelli G; Latronico MV; Condorelli M
    Heart Fail Monit; 2008 Feb; 5(4):112-8. PubMed ID: 18273494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [On cardiac dynamics in the phase preceding right hypertrophy and on its electrocardiographic aspect in man].
    MAESTRINI D
    Policlinico Prat; 1959 Oct; 66():1409-13. PubMed ID: 13853750
    [No Abstract]   [Full Text] [Related]  

  • 17. EXPERIMENTAL cardiac hypertrophy.
    South Med J; 1952 Jul; 45(7):669-70. PubMed ID: 12984222
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.
    Zhang L; Jaswal JS; Ussher JR; Sankaralingam S; Wagg C; Zaugg M; Lopaschuk GD
    Circ Heart Fail; 2013 Sep; 6(5):1039-48. PubMed ID: 23861485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [EFFECT OF AMINOPTERIN ON COMPENSATORY HEART HYPERTROPHY].
    DERGACHEV VV
    Biull Eksp Biol Med; 1964 Sep; 58():31-4. PubMed ID: 14275522
    [No Abstract]   [Full Text] [Related]  

  • 20. Adrenal cortex and the heart.
    Kölbel F; Krulik R; Schreiber V
    Acta Cardiol; 1991; 46(3):323-8. PubMed ID: 1833940
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.